

Day 1 - 19th July 2024
07th Masterclass In Lung Cancer
Venue - The Learning Galaxy, 8th floor, Urmi Estate, Lower Parel, Mumbai.

Time	Topic	Speaker
	Welcome & Introduction	Dr. Vanita Norohna, Mumbai
09:00 - 11:00 AM	Geriatric Oncology Workshop	Dr. Vanita Norohna, Mumbai
11:00 - 01:00 PM	Radiology Workshop	Dr. Amit Janu, Mumbai
01:00 - 02:00 PM	Lunch	
	Early Lung Cancer	
	Chairpersons:	Dr. Ramakant Deshpande, Mumbai Dr. N K Warriar, Kochi Dr. Munish Gairola, Delhi
	Screening:	
02:00 - 02:15 PM	Screening & Prevention For Lung CA	TBC
	Preoperative Evaluation:	
02:15 - 02:25 PM	Preop Evaluation For Surgical Fitness Of Surgery In Early Stage Lung Cancer	Dr. Prriya Eshpuniyani, Mumbai
02:25 - 02:35 PM	Mediastinal Evaluation For Early Stage Lung CA	Dr. Devayani Niyogi, Mumbai
	Management Of Early Stage Lung CA:	
02:35 - 02:45 PM	Surgery - Early Stage Lung Cancer	Dr. Virendra Tiwari, Mumbai
02:45 - 02:55 PM	SBRT- Early Stage Lung Cancer	Dr. Anil Tibdewal, Mumbai
	Chairpersons:	
02:55 - 03:05 PM	Early Stage Lung Cancer - Adjuvant Chemotherapy	Dr. Vijay Agarwal, Bengaluru
03:05 - 03:15 PM	Adjuvant Targeted Therapy In EGFR Mutated Lung Cancer	Dr. Venkata Pradeep Babu, Assam
03:15 - 03:25 PM	Adjuvant Targeted Therapy In ALK+ Lung Cancer	Dr. Prasad Narayan, Bengaluru
03:25 - 03:35 PM	Neoadjuvant and Adjuvant Immunotherapy in Early stage Lung Cancer	Dr. Madala Ravikrishna, Hyderabad
03:35 - 03:45 PM	Follow Up After Treatment Completion In Early Stage Lung Cancer	Dr. Vikas Asati, Indore
03:45 - 04:30 PM	"Case Based Viva- 15 Min - History/Physical Examination 15 Min- Investigations 15 Min- Selection Of Treatment & Follow Up"	
	Moderator	Dr. Navneet Singh, Chandigarh
	Examinor	Dr. Ghansyam Biswas, Bhubneshwar
	Examinor	Dr. Manisha Singh, Patna
	Examinor	Dr. Rajesh Mistry, Mumbai
	Students: Ritika Hinduja/Suparna Rao /Hinduja Team	
	Immunotherapy: Stage 4 Non Driver Mutated PDL1 Positive	
04:30 - 04:40 PM	Interpretation Of PDL1 MSI TMB In NSCLC	Dr. Rajiv Kumar Kaushal, Mumbai
04:40 - 04:50 PM	Selection Of 1st Line Immunotherapy Pdl1 > 50% & 1% In NSCLC	Dr. Stalin Bala Chaudhary, Vizag
04:50 - 05:00 PM	Selection Of 1st Line Immunotherapy In PDL1 Negative & Non Driver Mutations	Dr. Manu Prasad, Kerala
05:00 - 05:10 PM	Biomarkers For Predicting Efficacy Of IO (Non PDL1 NON MSI NON TMB)	Dr. Kanika Sharma, Mohali
05:10 - 05:20 PM	Use Of Immunotherapy In Patients With Poor Performance Status	Dr. Anup Toshniwal, Aurangabad
05:20 - 05:30 PM	Use Of IO In Driver Mutated Patients	Dr. Manoj Mahajan Udaipur
05:30 - 05:40 PM	Mechanism Of Resistance On IO	Dr. Gautam Goyal, Chandigarh
05:40 - 05:50 PM	Therapy Post Progression On IO +/- Chemotherapy	Dr. Amol Patel, Lucknow

05:50 - 06:35 PM	Case Based Viva- 15 Min - History/Physical Examination 15 Min- Investigations 15 Min- Management	
	Moderator:	Dr. Govind Babu K, Bangalore
	Examiners:	Dr. Shekar Patil, Bangalore
	Dr Nandani/ Dr Anil T /dEVYANI	Dr. Jayant Gawande, Pune
		Dr. Sharmila Agarwal, Mumbai
		Dr. George Karimundackal, Mumbai
Day 2 - 20th July 2024		
07th Masterclass In Lung Cancer		
Venue - The Learning Galaxy, 8th floor, Urmi Estate, Lower Parel, Mumbai.		
Time	Topic	Speaker
08:55 - 09:00 AM	Welcome & Introduction	TBC
	Chairpersons	
	Locally Advanced Lung Cancer:	
09:00 - 09:10 AM	Chemotherapy In Locally Advanced Lung CA- NACT / Adjuvant	Dr. Swaratika Majumdar, Bangalore
09:10 - 09:20 AM	Neoadjuvant IO in locally advanced NSCLC	Dr. Mounika Boppana, Hyderabad
09:20 - 09:30 AM	Surgery After NACT In Locally Advanced Lung CA	Dr. Prasanth Penumadu, Tirupati
09:30 - 09:40 AM	Radiation In LALC	Dr. Srinivas Chilukuri, Chennai
09:40 - 09:50 AM	Concurrent Chemotherapy	Dr. Simit Sapkota, Nepal
09:50 - 10:00 AM	Maintenance Therapy In Locally Advanced Stage III NSCLC	Dr. Bivas Biswas, Kolkata
10:00 - 10:10 AM	Adjuvant IO in LALC	Dr. Minit Shah, Mumbai
10:10 - 10:35 AM	Debate : Resectable LA	
10 Min	CTRT followed by IO	Dr. Sudeep Das, Kolkata
	Vs	
10 Min	NEOADJUVANT IO FOLLOWED BY SURG/FOLLOWED BY IO	Dr. Sandeep Ishi, Nashik
5 Min	Rebuttal	
10:35 - 10:45 AM	HOW DO I MANAGE ACTIONABLE MUTATION POSITIBVE LALC	Dr. T P Sahoo, Bhopal
10:45 - 11:30 AM	Case For VIVA - NSCLC-Locally Advanced 15 Min - History/Physical Examination 15 Min- Investigations 15 min- Selection of therapy (RT versus Sx, NACT versus ACT, Role IO)	
	Moderator:	Dr. Purvish Parikh, Jaipur
	Examiners:	Dr. Arvind Kumar, Patna
		Dr. V Kannan, Mumbai
	Case Presentation	Dr. Amita Athavale, Mumbai
	3 Volunteer	Dr. Murad Lala, Mumbai
11:30 - 11:50 AM	Real Life Case Based Discussion	TBC
	EGFR Mutated Lung Cancer	
11:50 - 12:00 PM	Interpretation Of NGS What A Clinician Should Know	Dr. Amit Dutt, Delhi
12:00 - 12:10 PM	Osimertinib Or Decotinib As First Line Therapy In EGFR Mutated Lung Cancer	Dr. Rakesh Pinninti, Hyderabad
12:10 - 12:20 PM	First Line- TKI + Something In EGFR Mutated Lung Cancer	Dr. Siddharth Turkar, Raipur
12:20 - 12:30 PM	Mechanism Of Resistance To Osimeritinib In EGFR Mutated Lung Cancer	Dr. Tanmoy Kumar Mandal, Kolkata
12:30 - 12:40 PM	Post Osimeritinib Options In EGFR Mutated Lung Cancer	Dr. Somnath Roy, Kolkata
12:40 - 12:50 PM	Uncommon EGFR mutations	Dr. Pradeep Ventrapati, Vizag

12:50 - 01:10 PM	Sponsored session 3	
01:10 - 01:50 PM	Sponsored session 4	
01:50 - 02:35 PM	Lunch	
02:35 - 02:45 PM	Interpretation Of ALK	Dr. S P Shrivastava, Indore
02:45 - 02:55 PM	Selection Of 1st Line Therapy -1st Or 2nd Generation or 3rd ALK Inhibitors In ALK Rearranged NSCLC	Dr. Goli Vasu Babu, Vijayawada
02:55 - 03:05 PM	ALK variants and its response in first line to different TKI. Do we need to have different drugs for different variants	Dr. Kishore Kota, Vizag
03:05 - 03:15 PM	Molecular Resistance Mechanism Of ALK Inhibitors	Dr. Amol Dongre, Nagpur
03:15 - 03:25 PM	Selection Of Agent Post 2nd And 3rd Generation ALK Inhibitors Resistance	Dr. Ullas Batra, Delhi
03:25 - 04:05 PM	Sponsored session 5	
04:05 - 04:45 PM	Sponsored session 6	
04:45 - 05:00 PM	Tea Break	
05:00 - 06:00 PM	CART T Cell and Cellular Therapy Insights	
06:00 - 06:45 PM	Case Base VIVA- Driver Mutated NSCLC 15 Min - History/Physical Examination 15 Min- Investigations 15 Min- Management	
	Moderator:	Dr. Prabhat Malik, Delhi
	Examiners:	Dr. Bhavin Visariya, Mumbai Dr. N K Warriar, Kochi Dr. Rakesh Taran, Indore Dr. G. Sadashivudu, Hyderabad
06:45 - 07:45 PM	Sponsored session 7	
07:45 - 08:05 PM	Session Sponsored by BD/BARD	
	Choosing Right VAD in Cancer Patients.	TBC
08:05 PM Onwards	Closing Remarks Followed By Dinner	

Day 3 - 21st July 2024
07th Masterclass In Lung Cancer
Venue - The Learning Galaxy, 8th floor, Urmi Estate, Lower Parel, Mumbai.

Time	Topic	Speaker
08:55 - 09:00 AM	Welcome & Introduction	Dr. Vijay Patil, Mumbai
09:00 - 09:10 AM	LD SCLC- Radiation	Dr. Dodul Mondal, Delhi
09:10 - 09:20 AM	LD SCLC- Concurrent Chemotherapy	Dr. Amit Kumar, Patna
09:20 - 09:30 AM	LD SCLC- Neoadjuvant	Dr. Ashutosh Jain, Delhi
09:30 - 09:40 AM	ED- Selection Of First Line Chemotherapy	Dr. Vamshi Krishna, Hyderabad
09:40 - 09:50 AM	Selection Of Regimen- Poor PS & SVCO	Dr. Tarachand Gupta, Jaipur
09:50 - 10:00 AM	ED- SCLC - Selection of Immunotherapy	Dr. Sangeetha Parthiban, Vizag
10:00 - 10:10 AM	ED- Selection Of The Second Line And Beyond	Dr. Akansha Choudhary, AIIMS Bhopal
	KRAS	
10:10 - 10:20 AM	Interpretation Of KRAS Mutation	Dr. Rushabh Kothari, Ahmedabad

10:20 - 10:30 AM	Selection Of 1st Line Therapy For KRAS	Dr. Akhil Kapoor, Varanasi
10:30 - 10:40 AM	Mechanism Of Resistance To KRAS TKI And Therapy Post Resistance	Dr. Soumya Surath Panda , Bhubneshwar
	BRAF	
10:40 - 10:50 AM	Evaluation Of BRAF Mutation Testing Methodology: Technologies & Their Interpretation	Dr. Aparna Dhar, Delhi
10:50 - 11:00 AM	Selection Of 1st Line Targeted Therapy For BRAF Mutated NSCLC	Dr. Avinash Talele, Mumbai
11:00 - 11:10 AM	Mechanism Of Resistance To BRAF TKI And Therapy Post Resistance In BRAF Mutated NSCLC	Dr. Boman Dhabhar, Mumbai
11:10 - 11:30 AM	Sponsored Session 8	
	EXON 20	
11:30 - 11:40 AM	Interpretation Of Exon 20 Insertion	Dr. Amit Verma, Delhi
	Sponsored Session 9	
11:40 - 12:10 PM	Selection Of 1st Line Therapy For EXON 20 Insertion	
12:10 - 12:20 PM	Mechanism Of Resistance To EXON 20 Insertion TKI And Therapy Post Resistance	Dr. Chetan Deshmukh , Pune
	RET	
12:20 - 12:30 PM	Interpretation Of RET Mutation	Dr. Trupti Pai, Mumbai
12:30 - 12:40 PM	Selection Of 1st Line Therapy For RET	Dr. Sameer Shrirangwar, Nagpur
12:40 - 12:50 PM	Mechanism Of Resistance To RET TKI And Therapy Post Resistance	Dr. Vibhor Sharma, Delhi
	NTRK	
12:50 - 01:00 PM	Interpretation Of NTRK Mutation	Dr. Moushumi Suryavanshi, Delhi
01:00 - 01:10 PM	Selection Of 1st Line Therapy For NTRK	Dr. Pushpak Chirmade, Mumbai
01:10 - 01:20 PM	Mechanism Of Resistance To NTRK TKI And Therapy Post Resistance	Dr. Kripa Bajaj, Hyderabad
	MET	
01:20 - 01:30 PM	Interpretation Of MET Amplification On EXON 14 Skip Mutation In NSCLC	Dr. Sunil Pasricha, Delhi
01:30 - 01:40 PM	Selection Of 1st Line Therapy For MET Amplification And MET EXON 14 Mutation In NSLC	Dr. Partha S. Roy, Guwahati
01:40 - 01:50 PM	Mechanism Of Resistance To MET TKI And Therapy Post Resistance IN NSCLC	Dr. Adwaita Gore, Mumbai
	ROS	
01:50 - 02:00 PM	Interpretation Of ROS 1 Rearrangement In NSCLC	Dr. Anuradha Choughule, Mumbai
02:00 - 02:10 PM	Selection Of 1st Line Therapy For ROS 1 Rearrangement IN NSCLC	Dr. Sandeep Jasuja, Jaipur
02:10 - 02:20 PM	Mechanism Of Resistance To ROS 1and Therapy Post Resistance In NSCLC	Dr. Randeep Singh, Gurugram
02:20 PM Onwards	Closing Remarks Followed By Lunch	